Education
About Us
Working with TipRanks
Follow Us
HeartBeam (BEAT)
NASDAQ:BEAT
BEAT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.70 - $3.48
Previous CloseN/A
Volume12.23K
Average Volume (3M)66.72K
Market Cap
$67.45M
Enterprise Value$56.30M
Total Cash (Recent Filing)$45.26M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.86
Next Earnings
May 08, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding33,725,468
10 Day Avg. Volume53,978
30 Day Avg. Volume66,721
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.73
Forecast
1Y Price Target
$8.00Price Target Upside308.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
HeartBeam News
PremiumCompany Announcements
HeartBeam’s Earnings Call Highlights Strategic Progress
PremiumCompany Announcements
HeartBeam Advances Cardiac Care with FDA Clearance and New Innovations
PremiumCompany Announcements
HeartBeam, Inc. Advances Cardiac Monitoring Solutions
PremiumCompany Announcements
HeartBeam Appoints Robert Eno as New CEO---
Bulls Say, Bears Say
Bulls Say
Commercial StrategyThe company has launched an Early Access Program to validate messaging and marketing and to create a funnel of early adopter sites in preparation for pilot commercialization.
Regulatory ApprovalThe FDA granted clearance for HeartBeam’s at-home, high-fidelity heart monitoring technology, which is foundational for future advancements.
Technological InnovationHeartBeam received clearance for its core system, the first patient-held device leveraging vector technology that captures the heart’s electrical signals in three dimensions.
Bears Say
Market Penetration ChallengesThe commercial strategy is taking shape, with a focus on concierge and preventive cardiology practices and direct patient outreach.
---
Ownership Overview
12.70% Insiders
2.89% Mutual Funds
2.70% Other Institutional Investors
79.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $1.70 and its highest was $3.48 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $67.45M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is May 08, 2025 which is in 34 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Mar 13, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.01.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.16.
How many shares outstanding does HeartBeam have?
HeartBeam has 33,725,468 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went up 1.485%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
---
HeartBeam Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (308.16% Upside)
$8.00 (308.16% Upside)
Blogger Sentiment
Bullish
BEAT Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $80.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.22%
12-Months-Change
Fundamentals
Return on Equity
-221.11%
Trailing 12-Months
Asset Growth
-80.88%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
---
BEAT Company Deck
---
BEAT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, such as FDA clearance, successful fundraising, and strong market potential. Challenges include increased cash outflows and uncertainties in the FDA review timeline. However, the positive aspects significantly outweigh the negatives, indicating strong progress and future potential.Read More>---
BEAT Stock 12 Month Forecast
Average Price Target
$8.00
▲(308.16% Upside)
Technical Analysis
Best Analysts Covering BEAT
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
+4.30%
reiterated a buy rating 11 days ago
Copying Bill Sutherland's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +4.30% per trade.
---